3630 results for «933»
3630 results
CathWorks FFRangio: from clinical data to advanced patient care
21 May 2026 – From EuroPCR 2026
Explore the clinical value of the CathWorks FFRangio system through the lens of the ALL-RISE randomised controlled trial and its implications for daily practice. By reviewing the trial’s primary and secondary endpoints, examine how FFRangio may influence diagnostic assessment, treatment planning, and clinical decision-making in patients...
Artificial intelligence-powered precision: CT-guided PCI and the future of image-guided therapy
19 May 2026 – From EuroPCR 2026
Image-guided PCI is entering a new era, driven by artificial intelligence and advanced CT technologies that are reshaping how coronary interventions are planned and performed.
This EuroPCR 2026 session explores the integration of photon-counting CT into PCI workflows, highlighting its improved spatial resolution, enhanced plaque characterisation and...
Renal denervation in China: momentum, insights, and evolution
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session highlights the rapidly evolving clinical experience of renal denervation (RDN) in China following regulatory approval, with a focus on real-world practice and programme development.
It reviews how structured, patient-centred hypertension pathways are being integrated with RDN, alongside practical strategies for managing complex renal...
The metal-free strategy: shaping the new era of hybrid vessel restoration with DCB and BRS
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores the emerging metal-free strategy in coronary intervention, combining drug-coated balloons (DCB) and bioresorbable scaffolds (BRS) to support a “leave-nothing-behind” approach to vessel restoration.
It focuses on lesion preparation, scaffold sizing and deployment, and the integration of hybrid therapies to optimise procedural outcomes....
DCB: does coating morphology matter for distal embolisation and clinical outcomes?
20 May 2026 – From EuroPCR 2026
Drug-coated balloon (DCB) therapy continues to evolve, with increasing attention on how coating design may influence drug transfer, vessel response and downstream clinical outcomes.
This EuroPCR 2026 session examines the role of coating morphology, comparing amorphous and crystalline technologies and their implications for drug delivery efficiency and...
Rethinking stentless PCI strategy - Improving outcomes with Bioadaptor
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session explores contemporary PCI strategies through the concept of stentless intervention using the Bioadaptor device in complex coronary disease.
It highlights the bioadaptive design features of Bioadaptor and reviews the supporting clinical evidence, with a focus on how this technology may influence procedural outcomes.
The...
How to become a CHAMPION in LAA closure
19 May 2026 – From EuroPCR 2026
This session reviews the latest CHAMPION AF trial data and its implications for left atrial appendage (LAA) closure in patients with atrial fibrillation.
It explores how emerging evidence may influence clinical practice and patient selection, and how LAA closure could evolve across different atrial fibrillation populations.
A recorded...
MagicTouch sirolimus-coated balloon for coronary artery disease and peripheral artery disease treatment: where evidence meets experience
20 May 2026 – From EuroPCR 2026
This session examines the clinical evidence and experiential insights regarding the MagicTouch sirolimus-coated balloon (SCB) for treating coronary and peripheral artery disease. It reviews long-term comparative data versus paclitaxel-coated balloons, application techniques, integration into current practices, and findings from major trials such as SIRONA and SIMPLE-DM,...
Angiography-based physiology: time to change your routine clinical practice?
20 May 2026 – From EuroPCR 2026
This session offers a critical appraisal of angiography-based physiology, with a focus on virtual fractional flow reserve (vFFR) technology. It reviews the latest clinical evidence, including insights from the FAST study programme and the FAST III randomised controlled trial. Gain a clear understanding of current guideline...
Management of a patient with complex multivessel disease involving bifurcations
19 May 2026 – From EuroPCR 2026
Complex multivessel coronary disease involving bifurcations requires careful procedural planning, imaging guidance and tailored stent strategies.
This EuroPCR 2026 session combines live educational case with insights from the NAGOMI COMPLEX study to explore contemporary approaches to complex PCI. A key focus is placed on the role of...
Beyond visualisation: the value and future of 4D intracardiac echocardiography in tricuspid repair and replacement
20 May 2026 – From EuroPCR 2026
Explore the transformative role of 4D intracardiac echocardiography in guiding tricuspid edge-to-edge repair (TEER) and valve replacement for tricuspid regurgitation. This session highlights how real-time, high-resolution imaging enhances procedural efficiency and safety, reducing reliance on general anesthesia and shortening procedure times compared to traditional imaging modalities.
Landmark interventional randomised controlled trial data and practice guidelines to transform pulmonary embolism care
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents landmark randomised controlled trial data shaping interventional treatment of pulmonary embolism, with a focus on translating evidence into clinical practice.
It reviews the HI-PEITHO trial and its implications in intermediate-risk acute PE, where ultrasound-assisted catheter-directed thrombolysis (USCDT) reduced the composite endpoint of...
Where to leave less behind: non-invasive CT and angiography-derived physiology for DCB lesion selection
20 May 2026 – From EuroPCR 2026
This session elucidates the role of non-invasive coronary CT and angiography-derived physiology in guiding lesion selection for drug-eluting balloon PCI. It emphasises integrating anatomical and physiological data to refine lesion preparation, strategy, and validation beyond angiography, and identifies scenarios where DEB PCI may not be optimal,...
Early evidence from a next generation coronary sinus reducer for the treatment of coronary microvascular dysfunction
20 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents early clinical experience with a next-generation self-expanding nitinol coronary sinus reducer for patients with coronary microvascular dysfunction. It reviews practical aspects of device implantation and discusses initial findings from the SERRA I feasibility study, providing insight into this emerging therapeutic approach....
Reshaping what's possible in complex PCI with advanced sirolimus technology
21 May 2026 – From EuroPCR 2026
Focused on advancing complex PCI, this session explores strategies to minimise metal use through advanced sirolimus technologies and drug-coated balloon (DCB) therapies. It highlights the biological and pharmacokinetic characteristics of DCBs, key device design considerations, and practical approaches to less-metal PCI. Clinical cases illustrate challenges such...
Breaking the calcium challenge: the power of Hertz with LithiX intravascular lithotripsy
20 May 2026 – From EuroPCR 2026
Calcified coronary lesions remain a major challenge in PCI, particularly when lesion rigidity limits device delivery and optimal stent expansion.
This EuroPCR 2026 session focuses on contemporary calcium modification strategies and the role of the Hertz contact intravascular lithotripsy (HC-IVL) system in simplifying treatment of complex calcified...
From 3D coronary imaging to calcium modification: the future of PCI starts now
21 May 2026 – From EuroPCR 2026
The integration of advanced imaging and calcium modification techniques is reshaping percutaneous coronary intervention (PCI), offering new ways to plan and optimise complex procedures.
This EuroPCR 2026 session explores how 3D coronary imaging extends beyond conventional angiography to improve procedural planning and decision-making. It highlights the role...
High definition IVUS-guided treatment strategies in calcified stenoses
20 May 2026 – From EuroPCR 2026
Severely calcified coronary stenoses remain one of the most challenging subsets in contemporary PCI, requiring precise lesion assessment and tailored treatment strategies.
This EuroPCR 2026 session focuses on how high-definition intravascular ultrasound (IVUS) is changing the way these lesions are approached in daily practice.
HD-IVUS enables detailed detection...
Contemporary workflow for class IA PCI
19 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session presents a contemporary workflow for Class IA PCI, focusing on how coronary physiology can be used to better understand disease patterns and guide procedural strategy in complex interventions.
It explores the role of physiological assessment in refining decision-making, alongside new co- and tri-registration...
Evidence in action: advancing care for angina with Shockwave Reducer
20 May 2026 – From EuroPCR 2026
Despite major advances in coronary revascularisation and medical therapy, angina continues to represent a significant clinical burden, affecting both quality of life and long-term patient management.
This EuroPCR 2026 session explores the emerging role of the Shockwave Reducer as a therapeutic option in patients with persistent angina....
